Considering the strong potential of NKG2D CAR in AML, several approaches, such as AML treatment with DNA hypomethylating agents and small-molecule-based activation of KLF4, have been identified for improved immune surveillance through NKG2D CAR [84,85]. This evidence concerns the gene KLRK1 and acute myeloid leukemia.